Serum miR-300 as a diagnostic and prognostic biomarker in osteosarcoma

Liu, Jiandong; Xin, Qun; Tao, Chunsheng; Sun, Peng; Xu, Peng; Wu, Bing; Qu, Liang G.; Li, Shuzhong

doi:10.3892/ol.2016.5214

Cited by 20 publications

(14 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…For example, downregulation of miR-95-3p was found in osteosarcoma patients compared to healthy controls, and low miR-95-3p expression was positively correlated with clinical stage and metastasis, as well as shorter survival and disease-free survival, indicating miR-95-3p served as a tumor suppressor in osteosarcoma [ 10 ]. Conversely, Liu et al showed miR-300 levels in osteosarcoma cases were significantly higher than those in healthy controls, and aberrantly elevated miR-300 expression was associated with worse prognosis of patients, suggesting an oncogenic role of miR-300 [ 11 ].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Diagnostic and prognostic implications of serum miR-101 in osteosarcoma

Yao

Liang

et al. 2018

CBM

View full text Add to dashboard Cite

Blood-circulating microRNAs (miRNAs) have been reported to be used as potential biomarkers in various cancers. MiR-101 has been found to act as a tumor suppressor in many tumor types, but little is known for osteosarcoma. The purpose of this study was to investigate miR-101 expression in osteosarcoma patients and assess its correlation with clinical features and prognosis. Serum samples from 152 osteosarcoma patients and 70 healthy controls were detected using quantitative reverse-transcription polymerase chain reaction (qRT-PCR). The data showed that miR-101 expression levels were remarkably underexpressed in serum samples from osteosarcoma patients compared to controls, and the post-treatment serum miR-101 expression was significantly higher than that in the pre-treatment expression. Low serum miR-101 expression was positively associated with advanced clinical stage and distant metastasis. Receiver operating characteristic (ROC) curve analysis showed that serum miR-101 could serve as a useful marker for osteosarcoma diagnosis, with a high sensitivity and specificity. Moreover, patients with high miR-101 expression had longer overall survival and recurrence free survival than those with low miR-101 expression. In addition, both univariate and multivariate analyses showed that serum miR-101 downregulation was associated with shorter overall survival and recurrence free survival. Our present results implicated serum miR-101 might be a useful biomarker for the clinical diagnosis and prognosis of osteosarcoma.

show abstract

Section: Discussionmentioning

confidence: 99%

“…During tumor initiation and progression, miRNAs are found to involve in diverse biological processes, such as cell proliferation, invasion, metastasis and angiogenesis [ 8 , 9 ]. Several miRNAs, such as miR-95-3p [ 10 ], miR-300 [ 11 ], miR-101, are found to be aberrantly expressed in osteosarcoma.…”

Section: Introductionmentioning

confidence: 99%

Diagnostic and prognostic implications of serum miR-101 in osteosarcoma

Yao

Liang

et al. 2018

CBM

View full text Add to dashboard Cite

show abstract

“…Therefore, this meta-analysis was conducted based on the remaining 17 articles. 32 , 33 , 35 – 49 The main characteristics of the included articles are presented in Table 1 .…”

Section: Resultsmentioning

confidence: 99%

MicroRNAs as a novel class of diagnostic biomarkers for the detection of osteosarcoma: a meta-analysis

Liu

Chen

et al. 2017

OTT

View full text Add to dashboard Cite

MicroRNAs (miRNAs) have been considered as promising diagnostic biomarkers for many diseases, especially for cancers. Numerous studies have reported the value of miRNAs in the diagnosis of osteosarcoma (OS), but the results vary greatly across different studies. Therefore, we conducted this meta-analysis to assess the prospective diagnostic value of miRNAs in diagnosing OS. All relevant articles from prior to July 28, 2017 were selected from PubMed, EMBASE, Web of Science, Cochrane Library, Chinese National Knowledge Infrastructure, and Wan-fang databases. The Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2) was performed to assess the quality of each article. A random-effects model was used to pool the sensitivity and specificity of the positive likelihood ratio (PLR), negative likelihood ratio (NLR) and, diagnostic odds ratio (DOR) together with the area under the curve (AUC) to evaluate diagnostic values. Seventeen studies comprising 2,214 OS patients and 1,534 healthy humans were included in our meta-analysis. The pooled estimations indicated that the miRNAs had a high accuracy for diagnosing OS, with a sensitivity of 0.82, specificity of 0.88, PLR of 10.96, NLR of 0.20, DOR of 54.55, and AUC of 0.93. Twenty-five miRNAs were differentially expressed in OS, including 17 upregulated and 8 downregulated. These miRNAs were correlated with survival time, tumor size, cell differentiation, tumor node metastasis staging, metastasis, tumor/cell invasion, pathological type, and response to radiotherapy and chemotherapy. Several different miRNAs are expressed in OS, and some of them might be potential biomarkers for the early diagnosis of OS.

show abstract

“…Similarly to miR-199a-5p, serum miR-300 levels decreased in OS patients following curative surgery. High levels of miR-300 were detected in advanced clinical stages and in metastasis, and indicated as an independent predictor factor for poor overall survival and progression free-survival rate in OS [ 69 ]. Of note, the authors underscored an important limitation of using miR-300 as a single biomarker for early detection and monitoring of OS: in fact, circulating miR-300 has been involved in the pathogenesis of other cancers, such as glioma and head and neck squamous cell carcinoma [ 70 , 71 ].…”

Section: Serum Micrornasmentioning

confidence: 99%

Circulating biomarkers in osteosarcoma: new translational tools for diagnosis and treatment

et al. 2017

View full text Add to dashboard Cite

Osteosarcoma (OS) is a rare primary malignant bone tumour arising from primitive bone-forming mesenchymal cells, with high incidence in children and young adults, accounting for approximately 60% of all malignant bone tumours. Currently, long-term disease-free survival can be achieved by surgical treatment plus chemotherapy in approximately 60% of patients with localized extremity disease, and in 20–30% of patients with metastatic lung or bone disease. Diagnosis of primary lesions and recurrences is achieved by using radiological investigations and standard tissue biopsy, the latter being costly, painful and hardly repeatable for patients. Therefore, despite some recent advances, novel biomarkers for OS diagnosis, prediction of response to therapy, disease progression and chemoresistance, are urgently needed. Biological fluids such as blood represent a rich source of non-invasive cancer biomarkers, which allow to understand what is really happening inside the tumour, either at diagnosis or during disease progression. In this regard, liquid biopsy potentially represents an alternative and non-invasive method to detect tumour onset, progression and response to therapy. In this review, we will summarize the state of the art in this novel area, illustrating recent studies on OS. Although the data reported in literature seem preliminary, liquid biopsy represents a promising tool with the potential to be rapidly translated in the clinical practice.

show abstract

Serum miR-300 as a diagnostic and prognostic biomarker in osteosarcoma

Cited by 20 publications

References 36 publications

Diagnostic and prognostic implications of serum miR-101 in osteosarcoma

Diagnostic and prognostic implications of serum miR-101 in osteosarcoma

MicroRNAs as a novel class of diagnostic biomarkers for the detection of osteosarcoma: a meta-analysis

Circulating biomarkers in osteosarcoma: new translational tools for diagnosis and treatment

Contact Info

Product

Resources

About